Research On Migration And Treatment Mechanism Of Human Amnion Membrane Mesenchymal Stem Cells In Vivo Of Alzheimer's Transgenic Mouse Via Intravenous Transplantation

Alzheimer's disease (AD), is also known as senile dementia, It is a primary degenerative disease of central nervous system. So far, the researchers have not stop studying the pathogenesis and mechanism about Alzheimer's disease, but the treatment for this disease has yet to breakthrough. With the rapid development of cell engineering, the study of stem cell transplantation on the treatment of central nervous system disease has broken a new ground for treatment of Alzheimer's disease.Human amniotic mesenchymal stem cells (hAMSCs) is a pluripotent stem cells which was isolated and cultured recently. This study will further explore the transport in vivo, and the treatment mechanism in the brain tissue after the third generation of amniotic mesenchymal stem cells vein grafts in transgenic mice with Alzheimer's disease.The experiment was divided into three parts. Part I:the third generation of amniotic mesenchymal stem cells are isolated and cultured; Part II:The study about the transport in vivo of Alzheimer's disease mice after the third generation of amniotic mesenchymal stem cells vein graft in Alzheimer's disease transgenic mouse. PartⅢ:The research on treatment mechanism brain tissue of Alzheimer's disease mice after 31 days the third generation of amniotic mesenchymal stem cells vein grafting in Alzheimer's disease transgenic mouse.PartⅠ:We isolated human amniotic mesenchymal stem cells from the placenta, then cultured, expanded and passed on third generation in vitro. We selected the third human amniotic mesenchymal stem cells which maintain a good shape, and had vigorous growth to do the following experiments.PartⅡ:The third human amniotic mesenchymal stem cells were harvested and labeled by fluorescin, then adjusted to 1×106cell/mL.500μl of these stem cells were injected into the Alzheimer's disease transgenic mouse via the tail vein. We sectioned the frozen tissue, examined the transplantation and the survival of the third human amniotic mesenchymal stem cells in heart, liver, spleen, lungs, kidney and brain of Alzheimer's transgenic disease mice by the flsorescence microscopy at different times. We found that the fluorescin labeled's third generation of human amniotic membrane stem cells can nest to the liver, spleen, lungs and brain tissue of Alzheimer's disease transgenic mice and lived in these tissue of Alzheimer's disease transgenic mice at the time which we examined; But we could not find any the fluorescin labeled's third generation of human amniotic membrane stem cells in the heart and kidney tissue of Alzheimer's disease transgenic mice at the time which we examined. We found all of the mice growed very well, and we not found any adverse reaction in the Alzheimer's disease mice.PartⅢ:The third generation human amniotic stem cells were transplanted in the Alzheimer's disease transgenic mouse by vein graft. After 31 days, we examined the differentiation of the third generation human amniotic stem cells in the brain tissue of the Alzheimer's disease transgenic mouse by immunohistochemistry, then we studied the possible treatment mechanism. The results showed that the astrocyte, neural stem cells, neural progenitor cells and neurons in brain tissue of the Alzheimer's disease transgenic mouse could significantly increase, and there were no any tumors in the Alzheimer's disease transgenic mouse, their function of liver and kidney was healthy. The results showed that the third generation human amniotic mesenchymal stem cell transplantation by the tail vein graft to treatment the Alzheimer's disease transgenic mouse had a positive treatment effect, it was safe and feasible.This is the first time that human amniotic mesenchymal stem cells were used to examine the transport and live in vivo of the Alzheimer's disease transgenic mouse by the tail vein graft, and to study the possible treatment mechanism in the brain tissue of the Alzheimer's disease transgenic mouse after the third human amniotic mesenchymal stem cells were transplanted 31 days. The results were provided the theoretical basis and direct evidence for the future clinical experiment.